The Official Journal of EuroPCR and the European Association of Percutaneous Coronary Interventions (EAPCI)

Interventions for valvular disease and heart failure

Valvular heart interventions: advances from 2019 to 2020

EuroIntervention 2020;16:808-823. DOI: 10.4244/EIJ-D-20-00096

1. Department of Cardiology, National University of Ireland, Galway (NUIG), Galway, Ireland; 2. Department of Cardiology, Xijing Hospital, Xi’an, China; 3. Department of Cardiology, Radboud University, Nijmegen, the Netherlands; 4. CORRIB Research Center for Advanced Imaging and Core Lab, Galway, Ireland; 5. Department of Cardiology, Amsterdam University Medical Center, Amsterdam, the Netherlands; 6. Department of Internal Medicine, Cardiology Division, University of Campinas (UNICAMP), Campinas, SP, Brazil; 7. NHLI, Imperial College London, London, United Kingdom


Introduction

Percutaneous valve technologies have revolutionised the treatment of valvular heart disease (VHD) and emerged as an alternative treatment option in elderly patients at all levels of surgical risk. In 2019 and 2020, important advances in the field of valvular heart interventions were achieved. In this review, we present the most recent and relevant studies that have emerged on the transcatheter treatment of VHD in 2019 and 2020.

AORTIC STENOSIS

In August 2019, the U.S. Food and Drug Administration (FDA) approved the use of transcatheter aortic valve replacement (TAVR) for the treatment of symptomatic severe aortic stenosis (AS) in low-risk ...

Sign in to read and download the full article

Forgot your password?
No account yet? Sign up for free!
Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com

Read next article
Transcatheter edge-to-edge mitral valve repair with the PASCAL system: early results from a real-world series